Diagnostic, Therapeutic Predictive, and Prognostic Value of Neutrophil Extracellular Traps in Patients With Gastric Adenocarcinoma.
biomarker
neutrophil extracellular traps
peripheral blood
prognosis
stomach neoplasms
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
25
01
2020
accepted:
26
05
2020
entrez:
28
7
2020
pubmed:
28
7
2020
medline:
28
7
2020
Statut:
epublish
Résumé
Neutrophils are a significant population of infiltrated immune cells in the tumor microenvironment. Neutrophil extracellular traps (NETs) are implicated in the biological behavior of many malignant tumors. NETs can be degraded into soluble nucleosomes, leading to the release of fragments containing DNA and granule proteins into the peripheral blood (PB). Using human gastric cancer (GC) biopsies and PB samples, we investigated the specific value of NETs in GC from a clinical perspective. In summary, the formation of NETs was discovered in the tissue microenvironment and PB of GC patients. The amounts of NETs and neutrophil accumulation decreased from tumor tissue to paratumor tissue. In addition, the level of NETs in the PB gradually declined through the following patient populations: advanced disease patients, preoperative patients, postoperative patients, benign disease patients, and healthy controls. The levels of NETs in the plasma and serum were significantly correlated. As a serum biomarker, NETs had a better diagnostic value than carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) in GC. The neutrophil count and neutrophil to lymphocyte ratio (NLR) were significantly associated with the level of NETs in the PB. The existence of lymph node metastasis indicated a high level of NETs in the serum. Moreover, the level of NETs in the PB was inversely correlated with short-term efficacy in GC patients who had received advanced first-line treatment. The higher baseline level of NETs in the PB of patients with negative HER2 status was correlated with worse progression-free survival (PFS). And the level of NETs in the PB was a unfavorable independent prognostic factor for PFS in patients with advanced GC who had received first-line treatment. Thus, NETs have novel diagnostic, therapeutic predictive, and prognostic value in GC patients.
Identifiants
pubmed: 32714865
doi: 10.3389/fonc.2020.01036
pmc: PMC7344202
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1036Informations de copyright
Copyright © 2020 Zhang, Hu, Ma, Sun, Wei, Li, Wei, Zhang, Yang, Wang and Gu.
Références
Cancer Res. 2016 Mar 15;76(6):1367-80
pubmed: 26759232
Am J Pathol. 2018 Feb;188(2):367-377
pubmed: 29331492
Front Immunol. 2013 Mar 06;4:48
pubmed: 23508552
Oncoimmunology. 2016 Feb 18;5(5):e1134073
pubmed: 27467952
J Hepatol. 2017 Sep 21;:
pubmed: 28943296
Science. 2004 Mar 5;303(5663):1532-5
pubmed: 15001782
Nat Commun. 2016 Mar 21;7:11037
pubmed: 26996437
Hepatology. 2018 Oct;68(4):1347-1360
pubmed: 29631332
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Nat Med. 2009 Jun;15(6):623-5
pubmed: 19448636
Lancet. 2010 Aug 28;376(9742):687-97
pubmed: 20728210
Science. 2018 Sep 28;361(6409):
pubmed: 30262472
Cancer Res. 2016 Aug 1;76(15):4311-5
pubmed: 27402078
JCI Insight. 2019 Jul 25;5:
pubmed: 31343990
J Pathol. 2011 Nov;225(3):438-47
pubmed: 21826665
Sci Transl Med. 2018 Apr 11;10(436):
pubmed: 29643232
J Exp Med. 2019 Jan 7;216(1):176-194
pubmed: 30567719
J Surg Res. 2017 Dec;220:410-418.e1
pubmed: 28890131
Cancer Cell. 2012 Mar 20;21(3):309-22
pubmed: 22439926
Nat Med. 2010 Feb;16(2):219-23
pubmed: 20081861
Int J Clin Exp Pathol. 2015 Nov 01;8(11):14075-86
pubmed: 26823721
Am J Surg. 2015 Feb;209(2):333-7
pubmed: 25190544
Clin Cancer Res. 2019 Mar 15;25(6):1867-1879
pubmed: 30446590
PLoS One. 2016 May 02;11(5):e0154484
pubmed: 27136460
Drug Resist Updat. 2012 Feb-Apr;15(1-2):39-49
pubmed: 22335920